logo
logo
AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology
Start with:
✓Flexible Plans • $39/mo or $29/mo annual
✓AI + real-time funding intelligence
✓Never see duplicates in your feed
INDUSTRY FIRST

Hummingbird Bioscience Closes US$25 Million Investment With Series B Extension

May 11, 2020•over 5 years ago

Amount Raised

$25 Million

Round Type

series b

Copenhagen

Description

 Hummingbird Bioscience, an innovative biotherapeutics company focused on the discovery and development of new breakthrough therapies, has closed an extended Series B funding round of US$25 million. This brings the total capital raised through financing activities and strategic partnerships to more than US$65 million to date.

Company Information

Company

Hummingbird Bioscience

Location

Copenhagen, Capital Region Of Denmark, Denmark

About

Hummingbird Bioscience, founded in 2013 is predicated on the opportunity to leverage advances in systems and computational biology to develop new treatments for cancer and other diseases

Company News

(7 articles)
Wed, 25 Jun 2025 07:00:00 GMT

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready - GlobeNewswire

Mon, 03 Mar 2025 08:00:00 GMT

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept - PR Newswire

Thu, 27 Jun 2019 22:44:43 GMT

Hummingbird Bioscience - Crunchbase

Tue, 07 Jan 2025 08:00:00 GMT

Hummingbird Bioscience Licenses Novel Antibodies to Immunome - GlobeNewswire

Thu, 19 Oct 2023 07:00:00 GMT

Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) - PR Newswire

Wed, 23 Oct 2024 07:00:00 GMT

Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024 - GlobeNewswire

Mon, 23 Oct 2023 07:00:00 GMT

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023 - PR Newswire

FundzWatch™ Score

66
Medium Activity

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech